Prothena Corporation plc (PRTA) is a well-capitalized biotech company with value driven by partnered programs, potential royalties, and a focus on returning capital to shareholders. Recent restructuring positions Prothena as a highly capital-rich wind-down with substantial upside potential, making it a high-risk/high-reward investment opportunity in the biotech space.

Rocket Pharmaceuticals, Inc. (RCKT) was previously highlighted for its Phase 1 success and strong balance sheet, but has since depreciated 63%. Prothena Corporation plc (PRTA) is now in focus for its wind-down phase, partnered milestones, and potential capital return, offering investors a unique opportunity in the biotech sector.

Read more at Yahoo Finance: Prothena Corporation plc (PRTA): A Bull Case Theory